Evidence map›Paper›PMID 33798634›Full record

ArticleMolecular and cellular endocrinology2021

Newly developed radioimmunoassay for Human Angiotensin-(1-12) measurements in plasma and urine.

Sarfaraz Ahmad, Henry A Punzi, Kendra N Wright, Leanne Groban, Carlos M Ferrario

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Internalization of Angiotensin-(1-12) in Adult Retinal Pigment Epithelial-19 Cells.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2023
    Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Sarfaraz AhmadDepartment of General Surgery, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA. Electronic address: sahmad@wakehealth.edu.
Henry A PunziTrinity Hypertension & Metabolic Research Institute, UT Southwestern Medical Center, Carrollton, TX, 75006, USA.
Kendra N WrightDepartment of General Surgery, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.
Leanne GrobanDepartment of Anesthesiology, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.
Carlos M FerrarioDepartment of General Surgery, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA; Department of Physiology-Pharmacology, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA.
Wake Forest University · USSouthwestern Medical Center · US

Funding

Vaso-Hormonal Mechanisms in HypertensionP01HL051952 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DELL'ITALIA, LOUIS J. · 1994 to 2019
$34.8M
Angiotensin (1-12) and Hypertension in the ElderlyR21AG070371 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI FERRARIO, CARLOS M · 2021 to 2022
$426k
NHLBI NIH HHS P01 HL051952NIA NIH HHS R21 AG070371
6 · The paper itself

Abstract

The dodecapeptide angiotensin-(1-12) [Ang-(1-12)] functions as an intracrine/paracrine substrate for local production of angiotensin II. We developed a reliable and specific radioimmunoassay (RIA) method for the measurement of Ang-(1-12) in human plasma and urine using an affinity purified antibody fraction directed towards the C-terminus of the human Ang-(1-12) sequence. The RIA method was applied to quantify the Ang-(1-12) in plasma and urine collected from thirty-four human subjects (29 treated with antihypertensive medicines and 5 untreated patients). Plasma Ang-(1-12) level was significantly higher (P < 0.05) in patients with systolic blood pressure ≥140 mm Hg (n = 10) compared to the group with systolic blood pressure <140 mm Hg (n = 24). No significant difference (P = 0.22) was found in spot urine between the groups. Our study also shows that the polyclonal antibody neutralizes the cleavage sites of the human Ang-(1-12) from recombinant human chymase (rhChymase) and serum angiotensin converting enzyme (ACE) mediated Ang II generating hydrolysis. Overall, this newly developed RIA method is reliable and applicable to accurately quantify the Ang-(1-12) level in clinical samples (plasma and urine). Further, our in vitro neutralization study suggests that the anti-Ang-(1-12)-antibody might be used as an in vivo therapeutic agent for preventing Ang-(1-12)/Ang II-mediated hypertension and organ damage.

Indexed as

AgedAngiotensin IIAngiotensinogenAntibodiesAntihypertensive AgentsBlood PressureCase-Control StudiesChymasesFemaleGene Expression RegulationHumansHypertensionLimit of DetectionMaleMiddle AgedPeptide Fragmentsangiotensin-(1-12), humanAngiotensin IIAngiotensinogenAntibodiesAntihypertensive AgentsChymasesCMA1 protein, humanPeptide FragmentsRecombinant ProteinsAngiotensin-(1–12)Angiotensin IAngiotensin IIAngiotensinogenHypertensionRadioimmunoassayRenin-angiotensin system

Identifiers

PMID33798634
PMCPMC8694336
OpenAlexW3142001477

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.